Fig. 2

Second-line treatment regimens received by patients with NSQ/other histology in the pre-ICI and post-ICI periods. ^a Other treatments included cabozantinib (n = 1) and capmatinib (n = 2) in the pre-ICI period and dabrafenib plus trametinib (n = 1) in the post-ICI period. EGFR Epidermal growth factor receptor, ICI Immune checkpoint inhibitor, NSQ Non-squamous cell, TKI Tyrosine kinase inhibitor